2025 United Kingdom Age-Related Mascular Degeneration Revenue Opportunities Report
Description
The 2025 United Kingdom Age-Related Mascular Degeneration Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Age-related Mascular Degeneration by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Age-related Macular Degeneration (AMD) market in the United Kingdom are Regeneron Pharmaceuticals, Roche, Novartis, and Apellis Pharmaceuticals. Regeneron is known for its Eylea drug, which held the largest market share of 53.73% in the UK for AMD treatment in 2021. Roche markets multiple AMD drugs, including Lucentis, Vabysmo, and Susvimo, and is heavily invested in R&D for retinal diseases. Novartis offers Lucentis and Beovu, targeting wet AMD and is expanding clinical trials to broaden applications. Apellis, although pioneering in dry AMD treatment with Syfovre, recently faced UK regulatory rejection for this drug, yet remains active in research collaborations.
Johnson & Johnson also participates in the UK AMD space focusing on innovative therapies including gene therapies aimed at retinal diseases, with strong research programs dedicated to improving patient outcomes and managing disease burden. Partnerships with healthcare professionals and ongoing trials underline their commitment to addressing unmet needs in advanced retinal diseases like geographic atrophy, a late stage of dry AMD. Additionally, companies like Astellas and others collaborate with patient organizations such as the Macular Society to better understand patient needs and advance treatment solutions.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Age-related Mascular Degeneration by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Age-related Macular Degeneration (AMD) market in the United Kingdom are Regeneron Pharmaceuticals, Roche, Novartis, and Apellis Pharmaceuticals. Regeneron is known for its Eylea drug, which held the largest market share of 53.73% in the UK for AMD treatment in 2021. Roche markets multiple AMD drugs, including Lucentis, Vabysmo, and Susvimo, and is heavily invested in R&D for retinal diseases. Novartis offers Lucentis and Beovu, targeting wet AMD and is expanding clinical trials to broaden applications. Apellis, although pioneering in dry AMD treatment with Syfovre, recently faced UK regulatory rejection for this drug, yet remains active in research collaborations.
Johnson & Johnson also participates in the UK AMD space focusing on innovative therapies including gene therapies aimed at retinal diseases, with strong research programs dedicated to improving patient outcomes and managing disease burden. Partnerships with healthcare professionals and ongoing trials underline their commitment to addressing unmet needs in advanced retinal diseases like geographic atrophy, a late stage of dry AMD. Additionally, companies like Astellas and others collaborate with patient organizations such as the Macular Society to better understand patient needs and advance treatment solutions.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
